Atossa Genetics (NASDAQ:ATOS) Releases Earnings Results, Beats Expectations By $0.30 EPS

Atossa Genetics (NASDAQ:ATOS) released its quarterly earnings results on Tuesday. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.30, FiscalAI reports.

Atossa Genetics Price Performance

Shares of NASDAQ ATOS traded up $0.01 on Wednesday, hitting $2.15. The company’s stock had a trading volume of 1,957 shares, compared to its average volume of 112,249. Atossa Genetics has a 12-month low of $1.70 and a 12-month high of $14.85. The company has a market capitalization of $21.46 million, a price-to-earnings ratio of -0.69 and a beta of 1.38. The stock has a 50 day moving average of $2.36 and a 200-day moving average of $3.74.

Analyst Upgrades and Downgrades

A number of analysts have commented on ATOS shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Atossa Genetics in a research report on Tuesday, September 8th. Wall Street Zen upgraded Atossa Genetics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Atossa Genetics currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.33.

Atossa Genetics Company Profile

Atossa Genetics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for breast cancer and other breast-related conditions. The company’s research is centered on targeted treatments intended to address unmet needs in the prevention and treatment of breast cancer. Atossa’s lead program is (Z)-endoxifen, an oral selective estrogen receptor modulator being investigated primarily for estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.